01—Abstract
Summary
Summary of the 8-K/A filed May 9, 2019. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. filed an amendment to its May 8, 2019, 8-K filing on May 9, 2019, to correct typographical errors in its first-quarter 2019 financial results press release.
While the net loss for the quarter was reported correctly, specific line items within the Condensed Consolidated Statements of Operations, namely 'Other expense, net' for both the three months ended March 31, 2019, and 2018, contained errors. These errors consequently impacted the reported 'Net loss' figures for those periods. Investors should note that this amended filing primarily addresses internal reporting accuracy and does not introduce new operational or strategic information.
The core net loss figures, while restated, are still presented as losses, reflecting Moderna's ongoing investment phase. The company is emphasizing that the net loss itself was not the misstated figure, but rather the components leading to it. This amendment serves as a clarification of previously issued financial data.
02—Key points
Key Highlights
- Amendment to May 8, 2019, 8-K filing to correct typographical errors.
- Errors identified in the 'Other expense, net' line item of the Condensed Consolidated Statements of Operations for Q1 2019 and Q1 2018.
- These errors subsequently affected the reported 'Net loss' line item for the comparative periods.
- The corrected filing reaffirms the net loss for the first quarter of 2019, but provides revised supporting figures.
- The company is correcting prior period (Q1 2018) financial data as well, indicating a review of historical reporting.
- The filing explicitly states that the information is not deemed 'filed' under Section 18 of the Exchange Act, limiting liability for this specific amendment.
- Exhibit 99.1, the press release dated May 8, 2019, has been restated with corrections.
03—Questions
Frequently Asked Questions
What is the primary reason for this amended 8-K filing?
This amended 8-K filing is to correct typographical errors that were present in the original press release announcing Moderna's first-quarter 2019 financial results. Specifically, errors were found in the 'Other expense, net' line item and consequently in the 'Net loss' line item of the Condensed Consolidated Statements of Operations.
Did the net loss for Q1 2019 change significantly due to this correction?
The filing states that the net loss itself was accurately reported in the original press release. However, the figures contributing to that net loss, specifically 'Other expense, net,' contained typographical errors for both Q1 2019 and Q1 2018. This means the underlying components of the net loss were incorrect, but the final net loss figure reported in the original release was not the primary error.
Are there any new business or operational updates in this filing?
No, this filing is purely an amendment to correct typographical errors in previously reported financial data. It does not contain any new business developments, strategic updates, or forward-looking statements regarding Moderna's operations or pipeline.
What is the implication of the information not being 'filed' under Section 18 of the Exchange Act?
This means that investors cannot use this specific amended filing to claim liability against Moderna under Section 18 of the Securities Exchange Act of 1934 for any misstatements or omissions contained within it. It limits the legal recourse available to investors based solely on the content of this amendment.
04—Continue